Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.
Status:
Completed
Trial end date:
2020-03-06
Target enrollment:
Participant gender:
Summary
Proliferative diabetic retinopathy is a serious complication of diabetes mellitus, partly
consecutive to upregulation of vascular endothelial growth factor (VEGF) as a consequence of
retinal ischemia leads. Aflibercept has been approved by FDA and European medicine agency for
treatment of exudative age-related macular degeneration, another retinal disease
characterized by choroidal new vessels.
The aim of this pilot study is to evaluate the efficacy and the safety of Aflibercept
intravitreal injections compared to panretinal photocoagulation for proliferative diabetic
retinopathy.